Pota V, Coppolino F, Barbarisi A, Passavanti MB, Aurilio C, Sansone P, Pace MC. Pain in intensive care: a narrative review. Pain Ther. 2022;11(2):359–67.

Article  PubMed  PubMed Central  Google Scholar 

Baumbach P, Gotz T, Gunther A, Weiss T, Meissner W. Prevalence and characteristics of chronic intensive care-related pain: the role of severe sepsis and septic shock. Crit Care Med. 2016;44(6):1129–37.

Article  PubMed  Google Scholar 

Leininger S. The challenges of managing pain in the intensive care unit. Crit Care Nurs Q. 2022;45(4):325–31.

Article  PubMed  Google Scholar 

Hughes LM, Irwin MG, Nestor CC. Alternatives to remifentanil for the analgesic component of total intravenous anaesthesia: a narrative review. Anaesthesia. 2023;78(5):620–5.

Article  CAS  PubMed  Google Scholar 

Wang W, He Q, Wang M, Kang Y, Ji P, Zhu S, Zhang R, Zou K, Sun X. Associations of fentanyl, sufentanil, and remifentanil with length of stay and mortality among mechanically ventilated patients: a registry-based cohort study. Front Pharmacol. 2022;13: 858531.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Battershill AJ, Keating GM. Spotlight on remifentanil: its analgesic and sedative use in the intensive care unit. CNS Drugs. 2006;20(6):519–22.

Article  PubMed  Google Scholar 

Karabinis A, Mandragos K, Stergiopoulos S, Komnos A, Soukup J, Speelberg B, Kirkham AJ. Safety and efficacy of analgesia-based sedation with remifentanil versus standard hypnotic-based regimens in intensive care unit patients with brain injuries: a randomised, controlled trial [ISRCTN50308308]. Crit Care. 2004;8(4):R268-280.

Article  PubMed  PubMed Central  Google Scholar 

Wilhelm W, Kreuer S. The place for short-acting opioids: special emphasis on remifentanil. Crit Care. 2008;12(Suppl 3):S5.

Article  PubMed  PubMed Central  Google Scholar 

Markham A. Oliceridine: first approval. Drugs. 2020;80(16):1739–44.

Article  CAS  PubMed  Google Scholar 

DeWire SM, Yamashita DS, Rominger DH, Liu G, Cowan CL, Graczyk TM, Chen XT, Pitis PM, Gotchev D, Yuan C, et al. A G protein-biased ligand at the mu-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine. J Pharmacol Exp Ther. 2013;344(3):708–17.

Article  CAS  PubMed  Google Scholar 

Tan HS, Habib AS. Oliceridine: a novel drug for the management of moderate to severe acute pain—a review of current evidence. J Pain Res. 2021;14:969–79.

Article  PubMed  PubMed Central  Google Scholar 

Gan TJ, Wase L. Oliceridine, a G protein-selective ligand at the mu-opioid receptor, for the management of moderate to severe acute pain. Drugs Today (Barc). 2020;56(4):269–86.

Article  CAS  PubMed  Google Scholar 

Viscusi ER, Skobieranda F, Soergel DG, Cook E, Burt DA, Singla N. APOLLO-1: a randomized placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the micro-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy. J Pain Res. 2019;12:927–43.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gelinas C, Johnston C. Pain assessment in the critically ill ventilated adult: validation of the Critical-Care Pain Observation Tool and physiologic indicators. Clin J Pain. 2007;23(6):497–505.

Article  PubMed  Google Scholar 

Muellejans B, Lopez A, Cross MH, Bonome C, Morrison L, Kirkham AJ. Remifentanil versus fentanyl for analgesia based sedation to provide patient comfort in the intensive care unit: a randomized, double-blind controlled trial [ISRCTN43755713]. Crit Care. 2004;8(1):R1–11.

Article  PubMed  Google Scholar 

Yang S, Zhao H, Wang H, Zhang H, An Y. Comparison between remifentanil and other opioids in adult critically ill patients: a systematic review and meta-analysis. Medicine (Baltimore). 2021;100(38): e27275.

Article  PubMed  Google Scholar 

Hammer GB, Khanna AK, Michalsky C, Wase L, Demitrack MA, Little R, Fossler MJ, Ayad S. Oliceridine exhibits improved tolerability compared to morphine at equianalgesic conditions: exploratory analysis from two phase 3 randomized placebo and active controlled trials. Pain Ther. 2021;10(2):1343–53.

Article  PubMed  PubMed Central  Google Scholar 

Biskupiak J, Oderda G, Brixner D, Wandstrat TL. Gastrointestinal adverse effects associated with the use of intravenous oliceridine compared with intravenous hydromorphone or fentanyl in acute pain management utilizing adjusted indirect treatment comparison methods. J Comp Eff Res. 2024;13(5): e230041.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Moss L, Hijma H, Demitrack M, Kim J, Groeneveld GJ, van Velzen M, Niesters M, Olofsen E, Dahan A. Neurocognitive effect of biased micro-opioid receptor agonist oliceridine, a utility function analysis and comparison with morphine. Anesthesiology. 2023;139(6):746–56.

Article  CAS  PubMed  Google Scholar 

Beard TL, Michalsky C, Candiotti KA, Rider P, Wase L, Habib AS, Demitrack MA, Fossler MJ, Viscusi ER. Oliceridine is associated with reduced risk of vomiting and need for rescue antiemetics compared to morphine: exploratory analysis from two phase 3 randomized placebo and active controlled trials. Pain Ther. 2021;10(1):401–13.

Article  PubMed  Google Scholar 

Khan ZH. Pain management in intensive care unit patients: the role of ultra-short acting opioid: remifentanil. Anesth Pain Med. 2013;3(1):188–90.

Article  PubMed  PubMed Central  Google Scholar 

Soergel DG, Subach RA, Sadler B, Connell J, Marion AS, Cowan CL, Violin JD, Lark MW. First clinical experience with TRV130: pharmacokinetics and pharmacodynamics in healthy volunteers. J Clin Pharmacol. 2014;54(3):351–7.

Article  CAS  PubMed  Google Scholar 

Nafziger AN, Arscott KA, Cochrane K, Skobieranda F, Burt DA, Fossler MJ. The influence of renal or hepatic impairment on the pharmacokinetics, safety, and tolerability of oliceridine. Clin Pharmacol Drug Dev. 2020;9(5):639–50.

Article  CAS  PubMed  Google Scholar 

Krafthofer J, Fabig SC, Baron R, Gierthmuhlen J. Pupillometry as a potential objective measurement of pain assessment in healthy volunteers. J Pain Res. 2024;17:2037–42.

Article  PubMed  PubMed Central  Google Scholar 

Singh A, Akhileshwar, Kumar N, De RR, Bahadur R, Shekhar S. The role of pupillometry in the assessment of pain in children under general anesthesia: a prospective single-blinded observational study. Cureus. 2023;15(8): e43894.

PubMed  PubMed Central  Google Scholar 

Lopez de Audicana-Jimenez de Aberasturi Y, Vallejo-Cueva A, Aretxabala-Cortajarena N, Rodriguez-Nunez C, Pelegrin-Gaspar PM, Gil-Garcia ZI, Rodriguez-Borrajo MJ, Marguello-Fernandez AA, Parraza-Diez N. The pupillary dilation reflex to a nociceptive stimulus as a tool for analgesia management: a diagnostic study. Aust Crit Care. 2024;37(2):230–5.

Article  PubMed  Google Scholar 

Casas-Alvarado A, Martinez-Burnes J, Hernandez-Avalos I, Mora-Medina P, Miranda-Cortes A, Dominguez-Oliva A, Mota-Rojas D. Assessment of the nociceptive response to the use of cannabidiol alone and in combination with meloxicam through infrared pupillometry in female dogs undergoing elective ovariohysterectomy. Front Vet Sci. 2024;11:1380022.

Article  PubMed  PubMed Central  Google Scholar 

Zhai Y, Cai S, Zhang Y. The diagnostic accuracy of critical care pain observation tool (CPOT) in ICU patients: a systematic review and meta-analysis. J Pain Symptom Manag. 2020;60(4):847-856 e813.

Article  Google Scholar 

Nazari R, Froelicher ES, Nia HS, Hajihosseini F, Mousazadeh N. Diagnostic values of the critical care pain observation tool and the behavioral pain scale for pain assessment among unconscious patients: a comparative study. Indian J Crit Care Med. 2022;26(4):472–6.

Article  PubMed  PubMed Central  Google Scholar 

Severgnini P, Pelosi P, Contino E, Serafinelli E, Novario R, Chiaranda M. Accuracy of Critical Care Pain Observation Tool and Behavioral Pain Scale to assess pain in critically ill conscious and unconscious patients: prospective, observational study. J Intensive Care. 2016;4:68.

Article  PubMed  PubMed Central  Google Scholar 

Gelina